162 related articles for article (PubMed ID: 37534509)
1. Is it time for age and clinically adjusted minimal residual disease interpretation in acute myeloid leukemia?
Ofran Y
Haematologica; 2024 Jan; 109(1):6-7. PubMed ID: 37534509
[No Abstract] [Full Text] [Related]
2. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
[TBL] [Abstract][Full Text] [Related]
3. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.
Oran B; Jorgensen JL; Marin D; Wang S; Ahmed S; Alousi AM; Andersson BS; Bashir Q; Bassett R; Lyons G; Chen J; Rezvani K; Popat U; Kebriaei P; Patel K; Rondon G; Shpall EJ; Champlin RE
Haematologica; 2017 Jan; 102(1):110-117. PubMed ID: 27540139
[TBL] [Abstract][Full Text] [Related]
4. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.
Onecha E; Linares M; Rapado I; Ruiz-Heredia Y; Martinez-Sanchez P; Cedena T; Pratcorona M; Oteyza JP; Herrera P; Barragan E; Montesinos P; Vela JAG; Magro E; Anguita E; Figuera A; Riaza R; Martinez-Barranco P; Sanchez-Vega B; Nomdedeu J; Gallardo M; Martinez-Lopez J; Ayala R
Haematologica; 2019 Feb; 104(2):288-296. PubMed ID: 30093399
[TBL] [Abstract][Full Text] [Related]
5. Advances in Genomic Profiling and Risk Stratification in Acute Myeloid Leukemia.
Richardson DR; Foster MC; Coombs CC; Zeidner JF
Semin Oncol Nurs; 2019 Dec; 35(6):150957. PubMed ID: 31759819
[TBL] [Abstract][Full Text] [Related]
6. The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia.
Qin YZ; Jiang Q; Wang Y; Jiang H; Xu LP; Zhao XS; Zhang XH; Liu KY; Huang XJ
Blood Cancer J; 2021 Apr; 11(4):67. PubMed ID: 33795645
[No Abstract] [Full Text] [Related]
7. Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia.
Tang FF; Xu LP; Zhang XH; Chen H; Chen YH; Han W; Wang Y; Yan CH; Sun YQ; Mo XD; Liu KY; Huang XJ
Br J Haematol; 2018 Feb; 180(3):448-451. PubMed ID: 27650511
[No Abstract] [Full Text] [Related]
8. Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia.
Sorigue M; Espasa A; Zamora L; Junca J
Ann Hematol; 2020 May; 99(5):1135-1136. PubMed ID: 32170360
[No Abstract] [Full Text] [Related]
9. Role of immunohistochemistry and flow cytometry in minimal residual disease detection in NPM1-mutated AML.
Aggarwal N; Alston ELJ; Pinkus GS; Weinberg OK
Int J Lab Hematol; 2022 Apr; 44(2):e76-e78. PubMed ID: 34704364
[No Abstract] [Full Text] [Related]
10. A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations.
Dvorakova D; Lengerova M; Pospisilova J; Palasek I; Mayer J
Leukemia; 2009 Apr; 23(4):793-6. PubMed ID: 18830256
[No Abstract] [Full Text] [Related]
11. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
12. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
13. Minimal Residual Disease in Acute Myeloid Leukemia.
Sung PJ; Luger SM
Curr Treat Options Oncol; 2017 Jan; 18(1):1. PubMed ID: 28110381
[TBL] [Abstract][Full Text] [Related]
14. Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach.
Wood BL
Curr Protoc Cytom; 2020 Jun; 93(1):e73. PubMed ID: 32311834
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of molecular MRD monitoring by next-generation sequencing in patients with
Shumilov E; Flach J; Joncourt R; Porret N; Wiedemann G; Novak U; Gfeller E; Jeker B; Amstutz U; Pabst T; Bacher U
Leuk Lymphoma; 2019 Oct; 60(10):2588-2590. PubMed ID: 30998101
[No Abstract] [Full Text] [Related]
16. Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia.
Murphy T; Zou J; Arruda A; Wang TT; Zhao Z; Zheng Y; Gupta V; Maze D; McNamara C; Minden MD; Schimmer A; Sibai H; Yee K; Capo-Chichi JM; Stockley T; Schuh A; Bratman SV; Chan SM
Haematologica; 2024 Feb; 109(2):671-675. PubMed ID: 37345484
[No Abstract] [Full Text] [Related]
17. Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia.
Yu T; Chi J; Wang L
Hematology; 2021 Dec; 26(1):848-859. PubMed ID: 34674615
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
19. NPM1 for MRD? Droplet Like It's Hot!
Wertheim GBW; Bagg A
J Mol Diagn; 2017 Jul; 19(4):498-501. PubMed ID: 28645444
[TBL] [Abstract][Full Text] [Related]
20. How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia?
Xu J; Jorgensen JL; Wang SA
Clin Lab Med; 2017 Dec; 37(4):787-802. PubMed ID: 29128069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
